Not Losing Weight on Ozempic? 7 Reasons and What to Try

The headline number from the STEP 1 trial is 14.9% body weight loss at sixty-eight weeks on semaglutide 2.4mg. It became the figure that launched a thousand telehealth ads, the statistic that anchored insurance negotiations, the benchmark patients brought to their first clinic visits.

What the headline tends to obscure is what John Wilding and his team reported alongside the average: the individual range was wide. Some participants lost more than 25% of their starting weight. Others lost less than 5%. The bell curve was real, and a meaningful slice of patients sat well below the mean.

If you are taking semaglutide and the scale is not moving the way the press releases suggested it would, you are not alone. You are also not necessarily doing anything wrong. The reasons that explain landing on the lower end of the distribution fall into a recognizable handful of categories. Most are addressable.

1. Dose and titration timing

Semaglutide for weight loss is dosed up gradually — 0.25mg for the first month, then 0.5mg, 1mg, 1.7mg, and eventually 2.4mg as the maintenance dose. The titration is designed to minimize gastrointestinal side effects, but it also means the full appetite-suppressing effect does not arrive until month five or later.

People who measure progress at month two or three are sampling the curve well before the dose has reached therapeutic range. The STEP 1 weight loss curve continued declining through week 68 — most of the loss happened in months four through twelve, not the first quarter. Patience with the titration period is part of the protocol, not an optional extra.

A related issue: some patients remain on a sub-maintenance dose because the higher dose produced too much nausea, or because their prescriber has not escalated them. The 1mg dose, used for diabetes, produces meaningfully less weight loss than the 2.4mg dose used for obesity. If you are still on 1mg or below for weight loss, that is likely a significant part of the explanation.

2. Protein is too low

Reduced appetite is the point of the medication. It is also a problem when it makes you stop eating enough protein to preserve lean mass.

A 2024 sub-study of STEP 1 patients led by Jennifer Linge used MRI to characterize body composition changes. Roughly 40% of total weight loss in some participants came from lean tissue. That ratio is concerning — losing muscle alongside fat means lower resting metabolic rate, weaker function, and a worse body composition than the scale weight alone reflects.

The mitigation, according to Stuart Phillips' work at McMaster University on protein needs during weight loss, is intake around 1.4 to 1.6 grams per kilogram body weight per day. For a 90-kilogram person, that is 125 to 145 grams of protein daily. On reduced appetite, hitting that target requires deliberate planning. Practical strategies for getting enough protein on GLP-1 tend to involve protein-first eating sequences, simple repeatable meals, and supplemental options like Greek yogurt or whey-based shakes.

People who lose substantial muscle along with fat often see scale weight changes that look reasonable but feel like progress has stalled — they are smaller but not stronger, and their resting expenditure has fallen with the muscle.

3. The food that is going in is the wrong food

GLP-1 medications reduce hunger. They do not change what food does in the body once swallowed. Patients who eat smaller portions of highly processed, calorie-dense food can technically be in caloric deficit but still produce slow weight loss because the food they are eating is poorly satiating, micronutrient-poor, and metabolically problematic.

The principle that Kevin Hall demonstrated with ultra-processed food — that the same calories produce different satiety and different metabolic effects depending on processing — does not disappear when you start a medication. It can be partially masked because appetite has been reduced from another direction, but the underlying dynamics still apply.

Patients who shift toward whole-food, protein-forward eating during GLP-1 therapy tend to see better outcomes than those who maintain the same eating pattern at smaller portion sizes. The medication does the work it can do. The food still matters.

4. Resistance training is missing

Cardio helps cardiovascular health. It does relatively little to preserve muscle mass during weight loss. Resistance training does — and the muscle preservation effect translates to better resting metabolic rate, better body composition, and lower regain risk if the medication is later discontinued.

Two to three resistance training sessions per week, focused on compound movements with progressive overload, is the evidence-based starting point. Practical implementation guidance covers the basic protocols. The combination of GLP-1 medication, adequate protein, and resistance training appears to substantially shift the lean mass loss curve in the patients who maintain it.

The patients who do not include resistance training, particularly older patients and those losing weight rapidly, often see body composition outcomes that disappoint relative to the scale number.

5. Sleep is wrecking it

Eve Van Cauter and Karine Spiegel's foundational work at the University of Chicago documented what happens to appetite hormones during sleep restriction. Four hours of sleep per night for several nights raises ghrelin by 15 to 28 percent, drops leptin, and shifts food preference toward calorie-dense, refined-carbohydrate options.

The hormonal pressure from sleep restriction works in the opposite direction from semaglutide. A patient sleeping six hours or less per night is essentially asking the medication to overcome a continuous hormonal headwind it was not designed to counter alone.

Sleep is also a significant predictor of which patients tolerate the medication well. Poor sleep amplifies nausea sensitivity, increases the likelihood of late-night eating that compounds GI side effects, and worsens the inflammatory baseline that many weight-loss attempts are trying to address.

6. Stress is elevated

Chronic psychological stress raises cortisol, and chronic cortisol elevation drives visceral fat retention, increases cravings for calorie-dense food, and blunts satiety signaling. Patients in high-stress life phases — caregiving, divorce, work crisis, financial pressure — often see weight loss that is slower than expected on the same medication dose.

This is not always addressable. Life circumstances are what they are. But naming the dynamic helps recalibrate expectations and points toward interventions (sleep prioritization, stress management, sometimes mental health support) that change the substrate the medication is working on.

7. Underlying medical factors

A short list of medical contributors that produce slower-than-expected GLP-1 response:

Hypothyroidism — even well-managed hypothyroidism can suppress resting metabolic rate enough to slow weight loss. TSH in the upper half of the normal range warrants discussion about whether the patient is functionally optimized.

PCOS — insulin resistance and hormonal dysregulation in polycystic ovary syndrome make weight loss harder through multiple mechanisms. GLP-1 medications can be particularly effective in this population but may require longer time horizons.

Medications that promote weight gain — beta-blockers, certain antidepressants (mirtazapine, paroxetine), insulin, sulfonylureas, antipsychotics, and corticosteroids all can work against weight loss. Review of the full medication list is part of the workup.

Perimenopause — the hormonal transition produces metabolic changes that slow weight loss and shift fat distribution. Some clinicians recommend longer time horizons for response assessment in this population.

Discussion with the prescribing clinician about whether any of these factors apply is appropriate if weight loss is meaningfully below expected at month six on a maintenance dose.

What "not losing weight" actually means

One reframe worth considering: scale weight is a noisy metric that captures only a portion of what is happening. Patients who are not losing weight on the scale may be losing fat while gaining muscle, particularly if they are training. Waist measurement, how clothes fit, and body composition assessment (DEXA or BodPod where available) give a more complete picture than weight alone.

The STEP 1 data also shows that some patients are simply non-responders or low responders — biology that does not respond to GLP-1 monotherapy in the same way the average patient does. For these patients, tirzepatide (which targets both GLP-1 and GIP receptors) sometimes produces better results, and combination approaches are emerging in clinical practice.

If you are at month six on the maintenance dose with optimized lifestyle factors and weight loss is below 5%, that conversation about alternative approaches is reasonable to initiate.

Key takeaways

• STEP 1's 14.9% average obscured a wide range — meaningful proportions of patients lost much more or much less. Being below the average doesn't mean the medication isn't working.
• Most weight loss occurs in months four through twelve, after titration to the 2.4mg maintenance dose. Earlier assessment is sampling the curve too early.
• Protein intake (1.4–1.6 g/kg body weight), resistance training, and whole-food eating substantially affect both scale weight and body composition outcomes.
• Sleep restriction and chronic stress create hormonal headwinds that can blunt medication effect. Addressing these is part of optimization.
• Medical factors — thyroid function, PCOS, weight-promoting medications, perimenopause — are worth reviewing with the prescriber if response is below expected.
• Switching to tirzepatide or combination approaches is reasonable to discuss if optimized semaglutide therapy at month six produces less than 5% loss.